Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that ...

CNW/ - Sun Pharma Canada Inc., a wholly owned subsidiary of Sun Pharmaceutical Industries Limited ("Sun Pharma"), is pleased ...

Takeda’s zasocitinib has shown strong rates of skin clearance, as well as other benefits, in new study results regarding ...

In both trials, envudeucitinib showed greater skin clearance than placebo on both co-primary endpoints at week 16.

NB-UVB phototherapy may restore adalimumab efficacy in chronic plaque psoriasis after treatment failure. Learn more about ...

Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...

Patients with psoriasis are at increased risk for cataracts, uveitis, dry eye disease, glaucoma, retinal vein occlusion (RVO) ...

An 18-year-old woman presents with a 7-year history of moderate to severe chronic plaque psoriasis involving her scalp, trunk, bilateral upper and lower extremities, and nails. Her chief complaint was ...

Psoriasis can increase skin infection risk due to effects from the condition and its treatments. Learn about potential infections, symptoms, and preventive measures.

A 46-year-old man presents for his first dermatology consultation for worsening symptoms of plaque psoriasis and recent-onset joint pain. He reports “painful aching” and swelling of his finger joints, ...

Although some people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...